Seongnam, South Korea, August 14, 2026
SK bioscience has submitted a Clinical Trial Application (CTA) to the South African Health Products Regulatory Authority (SAHPRA) for a global pediatric Phase 1b clinical trial of RSM01, an RSV preventive antibody candidate licensed from the Gates Medical Research Institute (Gates MRI). The planned study represents an important step in the company’s expansion beyond traditional vaccine development into antibody-based infectious disease prevention. The Phase 1b trial is expected to enroll approximately 80 infants aged 2 weeks to 8 months and will primarily evaluate the safety and pharmacokinetic profile of RSM01. The company intends to use the study to assess the candidate’s clinical development potential and establish a foundation for subsequent late-stage development.
Phase 1b Trial to Evaluate RSV Prevention in Infants
The new global pediatric study will focus on safety and pharmacokinetics of RSM01 in very young infants, an important population for RSV prevention. Respiratory syncytial virus can cause serious lower respiratory tract infections in infants and young children, with disease burden particularly significant during the first months of life. The Phase 1b study will therefore provide an opportunity to evaluate the preventive antibody candidate in the population targeted for future RSV protection. SK bioscience said the approximately 80-participant trial is intended to advance clinical understanding of RSM01 and support decisions regarding its subsequent development. RSM01 was licensed by SK bioscience from Gates MRI in February 2026. Gates MRI conducted the candidate’s early research and Phase 1a development in adults. The planned pediatric Phase 1b program marks a progression from adult clinical development into infants and represents a significant milestone in the candidate’s global clinical pathway. By advancing RSM01 through its own development capabilities and global regulatory network, SK bioscience is seeking to establish the potential role of the antibody as an additional approach to RSV prevention.
Expanding Beyond Vaccines Into Antibody Prevention
The development of RSM01 reflects SK bioscience’s strategy to broaden its infectious-disease prevention portfolio beyond vaccines. The company has experience in areas including cell-culture influenza vaccines and pneumococcal vaccines and is now expanding into antibody-based preventive technologies. Preventive antibodies can provide passive immunity, which may be particularly relevant for very young infants who may have limitations in developing sufficient active immunity through direct vaccination. The global RSV prevention market is also creating opportunities for additional preventive technologies. According to the market research information cited by SK bioscience, the worldwide market for RSV preventive antibodies is projected to reach $4.5 billion by 2032. With preventive antibodies already commercialized in several markets, continued demand for protection against RSV among infants and young children is expected to support further development in this area.
Global Partnerships Strengthen Infectious Disease R&D
SK bioscience is building its next-generation infectious disease prevention capabilities through a growing network of global partnerships and technology collaborations. Its relationship with Gates MRI provides access to RSM01 and expands the company’s work into antibody-based RSV prevention, while other collaborations are supporting vaccine development and technology acquisition. The company has also highlighted its joint pneumococcal vaccine development partnership with Sanofi and the introduction of injectable rotavirus vaccine technology from the U.S. Centers for Disease Control and Prevention.
The CTA submission to SAHPRA demonstrates SK bioscience’s continued efforts to advance its infectious disease pipeline through global clinical development and regulatory engagement. If the Phase 1b study progresses successfully, the resulting safety and pharmacokinetic data could help inform the next stages of RSM01 development. The company said it plans to continue strengthening its capabilities across diverse prevention platforms to address unmet needs associated with infectious diseases. The advancement of RSM01 therefore represents a notable step in SK bioscience’s strategy to combine vaccine expertise, antibody technology, global partnerships, and clinical development to expand options for infectious disease prevention.
Source: SK bioscience press release



